Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men

Medical Science Monitor

Volumn 9, Issue 3, 2003, Pages

  Hernández, Cristina ^a   Lecube, Albert ^a   Barberá, Gloria ^a   Chacón, Pilar ^a   Lima, Joan ^a   Simó, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

E Selectin; Fibrates; Monocyte chemoattractant protein 1 (MCP 1); Statins; Vascular cell adhesion molecule 1 (VCAM 1); Vascular inflammation

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; CIGARETTE SMOKING; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; VASCULAR DISEASE;

ADULT; ANTILIPEMIC AGENTS; BEZAFIBRATE; BIOLOGICAL MARKERS; CHEMOKINE CCL2; E-SELECTIN; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE IV; INFLAMMATION MEDIATORS; LOVASTATIN; MALE; MIDDLE AGED; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0037353329     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bucher HC, Griffith LE, Guyatt GH: Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999; 19: 187-95
2. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA, 1998; 279: 1643-50
3. Davignon J, Laaksonen R: Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol, 1999; 10: 543-59
4. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res, 2000; 47: 648-57
5. Cortellaro M, Cofrancesco E, Boschetti C et al: Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb Haemost, 2000; 83: 549-53
6. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med, 1999; 340: 115-26
7. Gosling J, Slaymaker S, Gu L et al: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest, 1999; 103: 773-78
8. Beaumont JL, Carlson LA, Cooper GR et al: Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO, 1970; 43: 891-908
9. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T et al: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation anti serumlipids anti lipoproteins in postmenopausal women. Thromb Haemost, 2001; 85: 619-25
10. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997: 20: 1183-95
11. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest, 1955; 34: 1345-53
12. Semaan HB, Gurbel PA, Anderson JL et al: Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease. Cardiology, 2000; 93: 7-10
13. Blankenberg S, Rupprecht HJ, Bickel C et al: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation, 2001; 104: 1336-42
14. Hwang SJ, Ballantyne CM, Sharrett AR et al: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 1997; 96: 4219-25
15. Cockerill GW, Rye KA, Gamble JR et al: High-density lipoprotein inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol, 1995; 15: 1987-94
16. Laug U, Fata VL, Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem, 1997; 272: 31725-9
17. Lefer AM, Campbell B, Shin YK et al: Simvastatin preserves the ischemic-repefused myocardium in normocholesterolemic rat hearts. Circulation, 1999; 100: 178-84
18. Mueck AO, Seeger H, Wallwiener D: Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes, 2001; 109: 181-83
19. Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci, 1991; 88: 4651-5
20. Davenpeck KL, Gauthier TW, Lefer AM: Inhibition of endothelialderived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology, 1994; 107: 1050-8
21. De Caterina R, Libby P, Peng HB et al: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest, 1995; 96: 60-8
22. Pruefer D, Scalia R, Lefer AM: Simvastatin inhibits leukocyteendothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol, 1999; 19: 2894-900
23. Seeger H, Wallwiener D, Mueck AO: Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor-I in human endothelial cell cultures. Climacteric, 2001; 4: 209-14
24. Bloomfield Rubins H, Robins SJ, Collins D et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med, 1999; 341: 410-8
25. Nawa T, Nawa MT, Cai Y et al: Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun. 2000; 275: 406-11
26. Peter K, Weirich U, Nordt TK et al: Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis. Thromb Haemost, 1999; 82(Suppl 1): 38-43
27. Rohde LE, Lee RT, Rivero J et al: Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol, 1998; 18: 1765-70
28. Rasmussen LM, Hansen PR, Nabipour MT et al: Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J, 2001; 360: 363-70
29. Jackson SM, Parhami F, Xi XP et al: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol, 1999; 19: 2094-104
30. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human athromatous plaques. J Clin Invest, 1991; 88: 1121-27
31. Kowab MC, Recce R, Beyer S et al: Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis, 2000; 149: 323-30
32. Ortego M, Bustos C, Hernandez-Presa MA et al: Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, 1999; 147: 253-61
33. Bustos C, Hernandez-Presa MA, Ortego M et al: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998; 32: 2057-64
34. Egashira K, Ni W, Inoue S et al: Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res, 2000; 23: 353-8
35. Kim SY, Guijarro C, O'Donnell MP et al: Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int, 1995; 48: 363-71
36. Romano M, Diomede L, Sironi M et al: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest, 2000; 80: 1095-100
37. Alfon J, Guasch JF, Berrozpe M, Badimon L: Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis, 1999: 145: 325-31
38. Garlichs CD, John S, Schmeisser A et al: Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation, 2001; 13: 2395-2400
39. Delerive P, De Bosscher K, Besnard S et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem, 1999; 974: 32048-54
40. Lee H, Shi W, Tontonoz P et al: Role of peroxisome proliferatoractivated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res, 2000; 87: 516-21